Why Pharma Still Can't Crack Menopause (and It's Not for Lack of Trying)
About 6,000 women enter menopause daily in the U.S., and the market opportunity tops $120 billion. So why does the pharmaceutical industry keep stumbling on drugs for it? The answer involves ghost studies, broken trial designs, and a system that still treats half the population's health as a niche.
About 6,000 women enter menopause every single day in the United States. That's a small city, every day, crossing into a phase of life that can bring hot flashes, brain fog, sleep disruptions, vaginal dryness, and a grab bag of other symptoms. And yet the pharmaceutical industry, which has figured out how to edit genes and train immune cells to hunt tumors, still struggles to build drugs for this.
It's not that nobody's trying. It's that the system itself keeps getting in the way.
A $120 Billion Problem With a Tiny Medicine Cabinet
The global market for menopause therapeutics is estimated at roughly $15 to $19 billion currently, with projections reaching $24 to $29 billion by the early 2030s. Venture capital in women's health hit a record $2.6 billion in 2024, nearly doubling from $1.7 billion the year before. Biopharma's share of that funding surged to 34%, up from just 12% in 2021.
So the money is flowing. The demand is enormous. But the medicine cabinet for menopausal women remains shockingly bare. Only about 2 million prescriptions exist among 41 million eligible women ages 45 to 64. That gap isn't an accident; it's the result of decades of compounding obstacles.
Women's health still receives only about 6% of private healthcare funding. Think of it like a restaurant where most of the kitchen budget goes to a few dishes on the menu, while half the customers get told to just order off a limited specials board.
Hot Flashes Are the Easy Part
When drug developers look at menopause, they tend to zero in on vasomotor symptoms (the medical term for hot flashes and night sweats). Why? Because those symptoms are measurable. You can count them. You can track their severity. Clinical trials need clear, quantifiable outcomes to satisfy regulators, and hot flashes deliver that.
The FDA has approved a couple of non-hormonal options in this space. Astellas launched Veozah (fezolinetant) in 2023, targeting a brain receptor called NK3 that helps regulate body temperature. Bayer followed with Lynkuet (elinzanetant) in October 2025, which hits both NK1 and NK3 receptors. Bayer thinks Lynkuet could eventually top $1 billion in annual sales.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
But menopause is so much more than hot flashes. Brain fog, sleep disturbances, mood changes, joint pain, urinary issues: these symptoms don't come with tidy measurement scales. There's no standardized way to quantify "I can't think straight at 2 p.m." in a clinical trial. And without clean endpoints (the specific outcomes a trial is designed to prove), the FDA has no straightforward path to approve drugs for those symptoms.
It's a bit like trying to win a cooking competition where the judges only score presentation. Your flavor might be incredible, but if the rubric doesn't measure it, you're out of luck.
Trials Designed for a World That Doesn't Exist
Even when companies build promising drugs, getting them through clinical trials is its own nightmare. The women who need these treatments the most are often the hardest to recruit.
Consider the typical menopause patient: she's likely in her late 40s or 50s, potentially working full time, possibly caring for aging parents and teenage kids. Clinical trials demand regular site visits, rigid schedules, and weeks or months of commitment. The design of most trials simply doesn't account for the reality of these women's lives.
And then there's the awareness problem. According to Mayo Clinic data, 80% of symptomatic women don't even bring up their symptoms with a doctor. If women aren't seeking treatment in the first place, how do you fill a clinical trial? The recruitment pool shrinks before enrollment even opens.
The result is a vicious cycle. Limited research leads to limited awareness, which leads to limited trial participation, which leads to limited research. Round and round it goes.
The Ghost of the WHI Still Haunts the Lab
No discussion of menopause drug development is complete without the Women's Health Initiative (WHI), a landmark study from 2002 that linked hormone replacement therapy to increased risks of heart disease, stroke, and breast cancer. Those findings led the FDA to slap black box warnings on hormone therapies, and an entire generation of women and doctors became terrified of HRT.
The problem? The WHI studied older women, many well past the window where hormone therapy is most beneficial and safest. For women under 60, or within 10 years of menopause onset, the risk profile looks very different. Data from those younger cohorts actually showed reduced mortality and fewer fractures.
In February 2026, the FDA finally removed those black box warnings from six menopausal hormone therapy products, keeping only the endometrial cancer warning for certain estrogen-only formulations. It was a huge symbolic shift, acknowledging that the one-size-fits-all fear around hormones was outdated.
But the damage from two decades of caution runs deep. Trial designs still have to grapple with WHI-era concerns. Developers need large, long-term studies to prove safety in specific age groups. That costs money, takes time, and scares away investors who want faster returns.
The New Guard Is Trying Anyway
Despite the headwinds, a crop of companies is pushing forward. AbCellera dosed its first patients in a Phase 2 trial for ABCL635 in January 2026, another non-hormonal drug targeting the NK3 receptor for hot flashes. Daré Bioscience is working on treatments for menopause-related vaginal dryness. And Celmatix Therapeutics is taking perhaps the most ambitious swing of all: targeting ovarian aging itself, with a drug designed to slow egg release and potentially delay menopause by years.
Celmatix's approach is still in early stages (animal testing before human trials), but the ambition signals where the field wants to go. Rather than treating symptoms one by one, some developers are asking whether they can change the underlying biology.
Commercial success isn't guaranteed even after approval, though. Veozah's journey is a cautionary tale: despite being first to market, it ran into an FDA safety warning for rare liver complications and has faced reimbursement friction including prior authorization requirements. Getting a drug approved is hard. Getting it into patients' hands, and getting insurers to pay for it, is a whole separate battle.
The Real Barrier Isn't Science
The technology exists. The targets are increasingly understood. The capital is starting to arrive. What's lagging is the infrastructure: trial designs flexible enough for real women's lives, regulatory endpoints that capture the full spectrum of menopause, and a healthcare system that takes this condition as seriously as it takes, say, cardiovascular disease.
Women's health has historically been treated as a niche. Menopause, despite affecting roughly half the population at some point, has been treated as an inevitability to endure rather than a condition to treat. The February 2026 FDA decision on black box warnings was a meaningful step. So is the surge in VC funding.
But closing a gap this wide will take more than a few milestone moments. It will take a fundamental rethinking of how we design trials, define success, and allocate resources in drug development. Until then, 6,000 women a day will keep crossing that threshold with fewer options than they deserve.
4 min read
The CAR-T Startup Betting $110M It Can Crack Liver Cancer
A Shanghai biotech just raised $110 million to chase what nobody has achieved: a CAR-T therapy that actually works against solid tumors. Oricell Therapeutics is betting it can crack liver cancer and IPO on the other side.
